In 2019, Apheris was founded with a singular vision: to solve one of pharmaceutical research's most persistent challenges. The founders recognized that while AI held immense promise for drug discovery, the most valuable data remained locked away in proprietary silos, inaccessible due to privacy, security, and IP concerns. Traditional approaches required data centralization - a non-starter for pharmaceutical companies fiercely protective of their research assets. This insight sparked the creation of Apheris, a platform that would enable collaboration without compromise.
Today, Apheris powers the world's leading federated life sciences data networks, enabling pharmaceutical companies to train superior AI models on distributed, proprietary datasets without ever moving or exposing sensitive information. Through the Apheris Gateway, organizations maintain complete data sovereignty while participating in industry-wide collaborations like the AI Structural Biology (AISB) Network, which brings together eight top-20 pharma companies including AbbVie, AstraZeneca, and Johnson & Johnson. By deploying secure, local applications for drug discovery - from co-folding models to ADMET prediction - Apheris is fundamentally transforming how the pharmaceutical industry leverages AI, turning data isolation into collaborative advantage.
